Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPN) 
Introduction

Myeloid malignancies are stem cell-derived clonal disorders and include three broad clinicopathologic categories: acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). Such classification is however operational and not precise; for example, some patients present with histologic features that are reminiscent of both MPN and MDS and are assigned the diagnosis of 'MDS/MPN' overlap
. [2, 3] . These 'classic' MPD are (Table 1) [4] . Current classification of chronic myeloid neoplasms is semi-molecular although primarily based on myeloid cell morphology and presence or absence of effective haematopoiesis; Fig. 1 
The history of MPN dates back to 1951 when William Dameshek coined the term 'myeloproliferative disorders (MPD)' as a clinicopathologic category that included chronic myelogenous leukaemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF)
Small Molecule Screening Towards New Therapeutics Review Series now included in an expanded category of 'MPN', according to the World Health Organization (WHO) classification system, which also includes systemic mastocytosis (SM) and chronic neutrophilic (CNL) and eosinophilic (CEL) leukaemias
illustrates the histological hallmarks that distinguish MDS, MPN and MDS/MPN.
Pathogenetic breakthroughs in MPN began in 1960 when the Philadelphia (Ph) chromosome was described in CML [5, 6] . This historic discovery later (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) led to the identification of BCR-ABL1 as the disease-causing mutation in CML [7] [8] [9] . In 1993 and 1994, stem 
cell factor receptor (KIT) and platelet-derived growth factor receptor-␤ (PDGFRB) mutations were associated with SM (KIT D816V and KIT V560G) [10] and an MPN phenotype characterized by eosinophilia and monocytosis (ETV6-PDGFRB) [11]. In 1998, a fibroblast growth factor 1 (FGFR1) mutation was described in stem cell leukaemia/lymphoma (SCLL; ZNF198-FGFR1). In 2003, FIP1L1-PDGFRA, a karyotypically occult platelet-derived growth factor receptor-␣ (PDGFRA) mutation, was described in association with an MPN phenotype characterized by eosinophilia and mastocytosis [12]. The molecular pathogenesis of BCR-ABL1-negative classic MPN remained elusive until early 2005 [13-16] when several groups reported a Janus kinase 2 (JAK2) gain-of-function (GOF) mutation (JAK2V617F) in PV, ET and PMF. In 2006, a GOF thrombopoietin receptor (MPL) mutation (MPLW515L) was reported in JAK2V617F-negative PMF [17]. In 2007, other JAK2 mutations (exon 12 mutations) in
JAK2V617F-negative patients with PV were described [18] .
Additional MPL and JAK2 exon 12 mutations have since been added to the list [19-21]. The above-listed revelations in putative disease-causing or disease-promoting genetic changes have ignited much interest in the development of molecular targeted therapy in MPN. Proof-ofprinciple in this regard has already been accomplished with the use of imatinib mesylate (IM) in CML [22] and PDGFR-rearranged MPN [12, 23]. On the other hand, therapeutic targeting of KITD816V or mutant FGFR1 has not been as successful whereas phase I/II clinical trials evaluating anti-JAK2 drugs are currently ongoing. In this review, I will provide a clinically relevant overview of mutant molecules of interest in adult MPN and discuss the current state of affairs in regards to targeted therapy.
BCR-ABL1
The stage for the discovery of BCR-ABL1 in CML was set in 1960 when Peter Nowell and David Hungerford described the Ph chromosome [5] . In 1967, Philip Fialkow and colleagues applied polymorphisms in the X-linked glucose-6-phosphate dehydrogenase (G-6-PD) locus to establish CML as a stem cell-derived clonal disorder [24] . In 1972, Janet Rowley clarified the constitution of the Ph chromosome as a reciprocal translocation between chromosomes 9 and 22; t (9;22)(q34;q11) [25] .
In 1982, the human homologue (ABL1; 225 kb total gene size) of v-abl was mapped to chromosome 9 [26] and shown to be involved in the Ph translocation [27] . In 1984 
The chromosome 9 [7, 8, [45] [46] [47] [87] [88] [89] and atypical CML (with minor response to imatinib) [85, [90] [91] [92] . Like BCR-ABL1, ETV6-ABL1 encodes for an activated and transforming ABL1 [87, 93] . The PNT oligomerization motif of ETV6 is thought to activate the ABL1 kinase by a similar mechanism to the BCR coiled coil oligomerization domain in the context of the BCR-ABL1.
Anti-BCR-ABL1 targeted therapy in CML
JAK2 and MPL mutations
Like ABL1, JAK2 is a cytoplasmic PTK and mutant JAK2, like mutant ABL1, has now been associated with classic MPN. JAK2 is a member of the Janus family of kinases that were incidentally discovered around 1989 and set aside as 'just another kinase' [94] . Their name was later modified to Janus kinases (JAKs) [95] [97] [106, 107, 115, 116] . [117] . In BCR-JAK2, the fusion protein includes the coiled-coil dimerization domain of BCR and the JAK2 kinase domain [112] . The patient in this particular instance had MPN-U and did not respond to imatinib. Another patient with BCR-JAK2 had AML [114] . The BCR-JAK2 fusion in this instance had a different BCR breakpoint, although it was similar to that of BCR-ABL1. The most recently described JAK2 fusion partner, SSBP2, is located at 5q14.1 and the associated phenotype was pre-B ALL [118] . The NH2 terminus of the SSBP2 protein contains a LisH motif that is believed to function as the dimerization domain. [13] [14] [15] [16] . Subsequently, the mutation has also described in other myeloid neoplasms [103, 119] . As of the time of this writing, JAK2V617F has not been reported in lymphoid disorders [120] [121] [122] [123] , solid tumour [124] [125] [126] [154, 155] . In the latter instance, both mutation positive and negative cells were shown to share the same cytogenetic abnormality and thus probably arose from a common ancestral clone [154] . On the other hand, JAK2V617F or other JAK2 mutations might be a necessary component of the PV phenotype, because they are detected in all patients with the disease [20] . Furthermore, recent studies suggest that germline genetic variation [156] and/or the occurrence of other concomitant mutations [19] might explain why the same mutation is present in apparently different disease phenotypes. [125, [157] [158] [159] [160] [161] [162] [163] . In addition, an activating JAK2T875N was described in an AMKL cell line [164] . There is no doubt that the list of such mutations will grow with time and, interestingly, some of the new mutations identified in PV co-existed with JAK2V617F.
Janus kinases
There are four JAKs (JAK1, JAK2, JAK3 and tyrosine kinase 2) and they all contain seven JH domains organized into four regions; kinase (JH1), pseudo-kinase (JH2), FERM (the N-terminal JH7, JH6, JH5, and part of JH4) and SH2-like (JH3 and part of JH4)
JAK2 fusion mutations GOF JAK2 fusion mutations have been associated with T or pre-B ALL, T-cell lymphoma, AML and MPN-U; these include ETV6-JAK2, t(9;12)(p24;p13), PCM1-JAK2, t(8;9)(p22;p24), BCR-JAK2, t(9;22)(p24;q11.2) and SSBP2-JAK2, t(5;9)(q14.1;p24.1) (Table 2) [106-114]. PCM1 displays multiple coiled-coil motifs and it is believed that these are preserved and function as a dimerization domain in PCM1-JAK2. In ETV-6-JAK2, the chimeric protein includes the Helix-Loop-Helix oligomerization domain of ETV6 fused to the kinase domain of JAK2 and the fusion oncogene induces both T and B cell lymphoid neoplasms in transgenic mice
In a more recent study, expression of ETV-6-JAK2 in human cord blood cells resulted in Epo-independent erythroid differentiation in vitro and induction of myelofibrosis in an in vivo xenotransplantation model
JAK2V617F
JAK2 V617F is an exon 14 G to T somatic mutation. The nucleotide change at position 1849 results in the substitution of valine to phenylalanine at codon 617. JAK2 V617F was first described in 2005 in patients with PV, ET and PMF
Other reported JAK2 exon 14 mutations include D620E (PV, MPN, unclassifiable), E627E (MPN, unclassifiable), K607N (AML), L611S (B-ALL), JAK2DeltaIREED (DS-associated B-ALL), C616Y (PV), V617F from c.1848_1849delinsCT (post-ET MF) and V617F/C618R from c.1849-1852GTCT Ͼ TTTC (PV)
JAK2 exon 12 mutations
In 2007, a set of JAK2 exon 12 mutations were described in JAK2V617F-negative patients with PV in whom erythrocytosis was the predominant feature [165] [20, [166] [167] [168] [169] [170] and in the process, most [20, 166, 167] but not all [168, 170] [172] and also occur in ET and 'idiopathic' abdominal vein thrombosis [173, 174] . Obviously, more studies are needed to fully appreciate the phenotypic spectrum of these mutations. [175] [176] [177] . The gene for MPL maps to chromosome 1p34 and contains 12 exons [178] . Germline MPL mutations have been associated with either familial thrombocytosis (GOF transmembrane domain mutation; S505N) [179] or congenital amegakaryocytic thrombocytopenia (LOF mutations) that often progresses to aplastic anaemia [180] [181] [182] 168] .
JAK2 mutations associated with trisomy 21 associated acute lymphoblastic leukaemia
In ET, the presence of JAK2V617F has been associated with advanced age, higher haemoglobin level, increased leukocyte count and decreased platelet count [136, [196] [197] [198] . In mutationpositive patients with ET, JAK2V617F allele burden has been directly correlated with leukocyte count, platelet count and the presence of palpable splenomegaly [136, 139, 140] . Similarly in PMF, the presence of JAK2V617F has been associated with an older age at diagnosis and higher leukocyte count [199] . In addition, JAK2V617F 'homozygous' PMF patients displayed an even higher incidence of leukocytosis, marked splenomegaly and pruritus [200] [136, 196] ; the impact on the risk of thrombosis or fibrotic transformation is less clear [136, 139, 196, 201] [137, 139, 194, 195] . In PMF, JAK2V617F presence was associated with inferior survival in one but not in another study [199, 202] . Similarly divergent results were reported in terms of leukaemic transformation rate and need for chemotherapy or splenectomy [200, 203] . The most recent study on the subject matter revealed shortened overall and leukaemia-free survival in PMF patients with lower as opposed to higher quartile JAK2V617F allele burden [203] . [209] . The drug's anti-JAK2 kinase activity was estimated at an IC50 of 6 nM, compared to 169 nM for JAK3 [209] . [209] . At similar or lesser drug concentrations, the drug also inhibited colony growth of primary cells from JAK2V617F-positive PV patients and MPLW515L-positve PMF patients [209] . [215] . In both instances, either the mutations themselves [215] [217] [218] [219] [220] [221] [222] . It is currently touted that all patients with MCD carry a KIT mutation but its laboratory detection might be hampered by the use of non-informative cell source or inadequate assay sensitivity [223, 224] . JM KIT mutations have also been described in canine mastocytomas [225] .
. Equally unclear is the prognostic relevance of JAK2V617F allele burden in PV where a higher mutant allele burden is implicated by some but not by others as an adverse prognostic factor for fibrotic transformation, thrombosis and need for chemotherapy
Anti-JAK2 small molecule therapy
A number of anti-JAK2 drugs have undergone preclinical testing and some have already been introduced into clinical trials [204]. Amongst them, some are JAK2 selective ATP-mimetic small molecules: e.g. TG101209, TG101348, INCB018424, XL019, CEP701 and SB1518 [205-208]. TG101209, an orally available small molecule JAK2-selective kinase inhibitor, is one of the first compounds to undergo extensive preclinical testing
In HEL cells (homozygous for JAK2 V617F) and other JAK2 V617F-transduced cell lines, TG101209 induced apoptosis and inhibited phosphorylation of JAK2V617F, STAT5 and STAT3 (IC50 of approximately 600 nM)
Furthermore, the growth inhibitory effect of TG101209 was relatively selective to mutated-colonies. TG101348, a drug that is very similar to TG101209, was also shown to display similar in vitro as well as in vivo anti-PV and anti-MPN activity in the context
Preliminary results regarding INCB018424 in PMF and post-PV/ET MF are encouraging in terms of the drug's toxicity profile and its activity against splenomegaly and constitutional symptoms [213]. More follow-up is required to determine the drug's effect on anaemia, leukoerythroblastosis, myelofibrosis, cytogenetic abnormalities or JAK2V617F allele burden. Results regarding other JAK2 inhibitors are too early to comment on. Nevertheless, the expected anti-inflammatory cytokine effect of this class of drugs is expected to be a confounding variable in terms of both toxicity and efficacy assessment.
KIT mutations
In 1993, Furitsu and colleagues described a mutant KIT allele with two-point mutations as being responsible for the ligand-independent constitutive activation of KIT in a human mast cell leukaemia cell line (HMC-1); one mutation was located at the JM region at codon 560 and nucleotides 1699-1701 (V560G; GTT → GGT) and the other at the kinase domain at codon 816 and nucleotides 2467-2469 (D816V; GAC → GTC) [10]. One year later (1994), Tsujimura et al. reported a kinase domain point mutation at nucleotide 2468 (GC to TA) resulting in an amino acid substitution at codon 814 (KITD814Y), in a murine mastocytoma cell line, P-815
KIT
KIT is located at chromosome 4q12 and encodes KIT, a class III receptor tyrosine kinase [226, 227] [228] . Normally, KIT is activated when bound to its ligand, the stem cell factor (SCF), which is encoded by SCF on chromosome 12q22 [229] [230] [231] [232] . KIT signalling and the corresponding cellular response depends on the specific cell type involved and the putative downstream effectors include PI3K-Akt, Src family of kinases, Ras-Erk, phospholipase C␥, MAPK and JAK-STAT [233] .
. The type III class also includes PDGFR, CSF-1 and Flt3 and is characterized by an extracellular component of five immunoglobulin-like domains, a trans-membrane segment, a juxtamembrane (JM) domain and a cytoplasmic kinase domain with a 70-100 amino acid kinase insert near its centre
. KIT (CD117) is notably expressed by mast cells, haematopoietic stem cells, germ cells, melanocytes and Cajal cells of the gastrointestinal tract and is therefore functionally relevant for mast cell development, haematopoiesis, gametogenesis and melanogenesis
Mutant KIT
Activating KIT mutations have been described in a spectrum of haematologic (e.g. mastocytosis, acute leukaemia) and nonhaematologic (e.g. gastrointestinal stromal cell tumour, germ cell tumour) malignancies [232] . Among these, SM is considered an MPN by virtue of its clonal derivation from the haematopoietic stem cell [234] [235] [236] . Observations from several laboratory studies support the oncogenic role of KIT mutations. For example, in murine experiments, D814Y has been shown to induce ligandindependent mast cell growth in vitro, tumourigenicity in vivo, and mast cell differentiation [237] . Similarly, retroviral infection of haematopoietic progenitors with mouse KITD814Y and KITV559G mutants induces autonomous myeloid and mast cell colony formation as well acute leukaemia in murine transplant models [238] . Furthermore, transgenic mice expressing KITD816V restricted to their mast cells display an SM phenotype that closely resembles the clinically heterogeneous disease in man [239] . This is in contrast to another report [240] that suggested a differentiating but not transforming potential for the mutation, which nevertheless probably participates in enhancing mast cell chemotaxis [241] and clustering [236] . Mutant Kit signalling might involve both PI3K [242] and Src [243] participation although utilization of pathway molecules might be different between the wild-type and mutant protein [244] .
Systemic mastocytosis
The 2008 World Health Organization (WHO) classification system for myeloid malignancies considers SM as a myeloproliferative neoplasm (MPN) [4] . WHO 
Targeted therapy in systemic mastocytosis
Although several drugs have shown in vitro anti-KIT activity [246] [247] [248] [249] [222, 250, 251] . Similarly, not all juxtamembrane mutations are sensitive to IM (e.g. V559I) [252] . Consistent with these in vitro observation, IM therapy is ineffective in SM associated with KITD816V [253] whereas others have shown activity in MCD associated with the trans-membrane KITF522C mutation [222] . In contrast to the experience from my own institution, Droogendijk et al. treated 11 patients with D816V-positive SM with 400 mg/day of IM and found some 'clinical improvement' in some patients [254] .
, the immediately most relevant, in terms of clinical development, include the tyrosine kinase inhibitors IM, nilotinib, dasatinib and PKC412. During in vitro experiments involving both cell lines and primary cells from patients with SM, IM inhibited wild-type KIT and KIT mutants with trans-membrane (F522C) and juxta-membrane (V559G and V560G) but not kinase (D816V or D814V) domain mutations
Nilotinib is more potent than IM in its in vitro anti-BCR-ABL activity but is similarly ineffective against KITD816V [255] . Other studies have, however, shown a more promising activity of nilotinib against kinase domain KIT mutations [256] . In contrast, dasatinib has shown potent anti-KIT activity in mast cell and leukaemia cell lines with different KIT mutants including those with D816V [257, 258] . In the largest study of dasatinib therapy in SM [259] , the drug was given at a starting dose of 70 mg PO bid to 33 SM patients: 18 indolent, 9 aggressive and 6 with associated non-mast cell myeloid neoplasm. Two (6%) patients, both of whom were D816V-negative, achieved complete remission. Nine (27%) patients experienced symptomatic improvement. The results of another case report series of four patients with SM treated with dasatinib were equally unimpressive [260] .
PKC412 has shown in vitro activity against transformed and primary cells with kinase domain KIT mutants (D816Y and D816V) [261, 262] . In a preliminary report, transient improvement in liver function test abnormalities, peripheral blood mast cell percentage and plasma histamine levels were seen in a patient with SM treated with PKC412 [263] . Similarly, oral PKC412 (100 mg bid) was administered to 15 SM patients (60% with detectable KITD816V) with evidence of clinical activity in 11 (73%) patients including increase in haemoglobin (n ϭ 1) and reduction of ascites (n ϭ 2) or pleural effusion (n ϭ 2). In four patients, the bone marrow mast cell burden was reported to have decreased from 50-60% to 10-15% range. [12] . Subsequent studies have demonstrated the stem cell origin of the particular mutation [264, 265] and functional studies have demonstrated transforming properties in cell lines and the induction of MPD in mice [266, 267] . Cloning of the FIP1L1-PDGFRA fusion gene identified a novel molecular mechanism for generating this constitutively active fusion tyrosine kinase, wherein ã 800 kb interstitial deletion within 4q12 fuses the 5' portion of FIP1L1 to the 3' portion of PDGFRA [12] . Molecular studies have shown that the breakpoint in FIP1L1 is relatively promiscuous, whereas the PDGFRA breakpoint is restricted to exon 12 that encodes part of the protein-protein interaction module with two fully conserved tryptophans (WW domain) containing the JM region with resultant disruption of its autoinhibitory activity [268] . Further biochemical analysis has shown that, in contrast with most tyrosine kinase fusions associated with human cancers, the FIP1L1 encoded sequences are dispensable for transformation, and there is no requirement for a dimerization motif; disruption of the autoinhibitory juxtamembrane motif as an invariant consequence of disruption of exon 12 is the basis for constitutive activation of PDGFRA kinase activity [269] .
PDGFR mutations
PDGFRA mutations
In regards to PDGFRA mutations, the most intensively studied has been the FIP1L1-PDGFRA, a karyotypically occult del(4)(q12), that was described in 2003 as an imatinib-sensitive activating mutation
FIP1L1-PDGFRA occurs in a very small subset of patients who present with the phenotypic features of either SM or HES but the presence of the mutation reliably predicts complete haematologic and molecular response to imatinib therapy [67, 69, 270] . FIP1L1-PDGFRA mutation (T674I) that is homologous to the resistanceinducing, 'gatekeeper' T315I mutation in BCR-ABL has been described [12, 271, 272] and in vitro salvage with other kinase inhibitors including PKC412 [266] and sorafenib [273] has been demonstrated whereas such activity has not been conclusively shown for nilotinib [274, 275] .
PDGFRA activation associated with CEL has also been described with karyotypically apparent fusion mutations including KIF5B-PDGFRA, t(4:10)(q12;p11) [276] , BCR-PDGFRA, t(4;22)(q12;q11) [277] and CDK5RAP2-PDGFRA, ins(9;4)(q33;q12q25) [278] . In the former instance, the breakpoints involved exon 3 of the kinesin family member 5B and exon 12 of PDGFRA resulting in an in-frame fusion. The patient achieved complete haematological and molecular remission with imatinib therapy [276] . BCR-PDGFRA represents an in-frame fusion with BCR breakpoints in intron 7/exon 12/exon 1/exon 17 and PDGFRA breakpoint in exon 12/exon 13 and is also sensitive to imatinib therapy [277, 279, 280] . CDK5RAP2-PDGFRA also represents an imatinib-sensitive in-frame fusion involving exon 13 of CDK5RAP2 and intron 9/exon 12 of PDGFRA [278] . As is the case with FIP1L1-PDGFRA, currently known PDGFRA breakpoints are noted to be tightly clustered in the JM region, which once again highlights a key regulatory role for this domain.
PDGFRB mutations
The [281] . Since then, several other PDGFRB fusion transcripts with similar disease phenotypes have been described [282] [283] [284] [285] [286] [287] [288] [289] [290] , cell line transformation [287] [288] [289] and MPD-induction in mice has been demonstrated [287] , and imatinib therapy was effective when employed [23, 283, 284, 286, 290] . Additional evidence regarding the oncogenicity of activated PDGFRB comes from experiments with mice where either ETV6-PDGFRB or H4-PDGFRB induced lymphoblastic lymphoma [289, 291] . In most of these mutations, PDGFRB is fused to the Nterminal segment of a partner protein that encodes for one or more oligomerization domains. [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [302] [303] [304] [305] [306] [307] .
FGFR1 mutations
In SCLL, FGFR1 mutation is present in both myeloid and lymphoid lineage cells and some of the associated fusion genes have [301, [308] [309] [310] and induce SCLL (ZNF198-FGFR1) [311] or CML (BCR-FGFR1) [310] 
